<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04590625</url>
  </required_header>
  <id_info>
    <org_study_id>Arise-FJ-O001</org_study_id>
    <nct_id>NCT04590625</nct_id>
  </id_info>
  <brief_title>Apatinib Combined With Abraxane and Carboplatin or Cisplatinum as First-line Treatment for Epithelial Ovarian Cancer</brief_title>
  <official_title>Apatinib Mesylate Combined With Albumin Binds Paclitaxel and Carboplatin or Cisplatinum as First-line Treatment for Stage II-IV Epithelial Ovarian Cancer Followed by Apatinib Maintenance Therapy:a Single-arm,Exploratory Clinical Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Zhongshan Hospital Xiamen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Zhongshan Hospital Xiamen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This monocentric, prospective, observational study will evaluate the safety and efficacy of&#xD;
      apatinib in combination with albumin binds paclitaxel and carboplatin or cisplatinum as&#xD;
      first-line treatment for stage II-IV epithelial ovarian cancer followed by apatinib&#xD;
      maintenance therapy in routine clinical practice. Eligible patients will be followed for&#xD;
      approximately 20 months.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">October 2020</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>defined as the proportion of patients with no gross tumor tissue residual after interval cytoreductive surgery</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression-free survival</measure>
    <time_frame>approximately 2 years</time_frame>
    <description>defined as time from first administration of first-line therapy to documented disease progression</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">58</enrollment>
  <condition>Ovarian Cancer</condition>
  <arm_group>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant therapy:&#xD;
Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.&#xD;
Neoadjuvant therapy is 3-4 cycles.After Neoadjuvant therapy will received interval cytoreductive surgery.&#xD;
Adjuvant therapy:&#xD;
After interval cytoreductive surgery,patients will received adjuvant therapy same as neoadjuvant therapy.&#xD;
Adjuvant therapy is 3 cycles&#xD;
maintenance treatment: After above treatment finished,patients will received aptinib for 2 years.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1.Adjuvant therapy:&#xD;
After primary cytoreductive surgery,patients will received adjuvant therapy:&#xD;
Apatinib:apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd; Abraxane:abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1; Cis-platinum or Carboplatin:cis-platinum or carboplatin one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1;carboplatin intravenous injection at a dose of AUC=5-6,d1.&#xD;
Adjuvant therapy is 3 cycles 3.maintenance treatment: After above treatment finished,patients will received aptinib for 2 years.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Apatinib Mesylate</intervention_name>
    <description>apatinib one course will last 21 days.Oral administration at a dose of 250 mg, qd</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Abraxane</intervention_name>
    <description>abraxane one course will last 21 days.Intravenously guttae at a dose of 260 mg/m2,d1</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cis Platinum</intervention_name>
    <description>cis-platinum one course will last 21 days.cis-platinum introperitoneal injection at a dose of 75-100 mg/m2,d1</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin</intervention_name>
    <description>carboplatin one course will last 21 days.carboplatin intravenous injection at a dose of AUC=5-6,d1</description>
    <arm_group_label>Group1</arm_group_label>
    <arm_group_label>Group2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        -&#xD;
&#xD;
        1.Age 18 - 75 years; 2.Histologically confirmed, stage II or IV epithelial ovarian&#xD;
        carcinoma; 3.For Group1,patients with stage III-IV ovarian cancer who are considered&#xD;
        unlikely to achieve satisfactory tumor reduction after preoperative evaluation by&#xD;
        gynecological oncologists or not suitable for direct surgery are required; 4.Patients with&#xD;
        at least one evaluable or measurable lesions as per RECIST version 1.1(CT scan length and&#xD;
        diameter of tumor lesion≥10mm CT scan of lymph node lesion was short diameter≥15mm,scan&#xD;
        slice thickness 5mm); 5.ECOG performance status (PS) 0 - 2; 6.Life expectancy of at least&#xD;
        12 weeks; 7.Patients with adequate organ function at the time of enrollment as defined&#xD;
        below:&#xD;
&#xD;
          1. Blood routine examination standard:(without blood transfusion within 14 days before&#xD;
             enrollment)&#xD;
&#xD;
               1. Hb ≥ 100g/L，&#xD;
&#xD;
               2. WBC ≥ 3.0×109/L&#xD;
&#xD;
               3. ANC ≥ 1.5×109/L，&#xD;
&#xD;
               4. PLT ≥ 100×109/L；&#xD;
&#xD;
          2. Biochemical examination shall meet the following standards:&#xD;
&#xD;
               1. BIL ≤ 1.5 times the upper limit of normal(ULN);&#xD;
&#xD;
               2. ALT and AST ≤ 3 ×upper limit of normal(ULN);&#xD;
&#xD;
               3. Serum creatinine Cr ≤ 1ULN;&#xD;
&#xD;
               4. Serum creatinine ALB ≥ 30g/L. 8.Women of childbearing age in the serum or urine&#xD;
                  pregnancy test is negative within 7 days prior to study enrollment and must be&#xD;
                  Non-lactating patients,and agree to use contraceptives (such as intrauterine&#xD;
                  devices, contraceptives or condoms) during the study period and within 8 months&#xD;
                  after the end of the study; males should agree to patients who must use&#xD;
                  contraception during the study period and within 8 months after the end of the&#xD;
                  study period.&#xD;
&#xD;
                  9.Subjects voluntarily joined the study, signed informed consent, good&#xD;
                  compliance, and followed up;&#xD;
&#xD;
                  Exclusion Criteria:&#xD;
&#xD;
                    1. Women who are pregnant or breastfeedind;&#xD;
&#xD;
                    2. Except for other malignant tumors, basal cell carcinoma of the skin and&#xD;
                       cervical cancer in situ in the past 5 years;&#xD;
&#xD;
                    3. Patients with symptomatic brain metastasis;Significant neurological or&#xD;
                       psychiatric disorders;&#xD;
&#xD;
                    4. Patients who have participated in other clinical trials in recent three&#xD;
                       months;&#xD;
&#xD;
                    5. Prior treatment with apatinib or other anti-vascular drugs and other small&#xD;
                       molecule tyrosine kinase inhibitors;&#xD;
&#xD;
                    6. Patients who have undergone systemic chemotherapy, radiotherapy, surgery,&#xD;
                       hormone therapy, or immunotherapy before enrollment;&#xD;
&#xD;
                    7. Within 3 months before treatment, there were esophageal (gastric fundus)&#xD;
                       varicose bleeding, intestinal obstruction and gastrointestinal perforation;&#xD;
&#xD;
                    8. Patients had clinically demonstrated cancerous ascites or pleural effusion;&#xD;
&#xD;
                    9. Patients has active infection or unexplained fever ≥38.5℃ within 7 days&#xD;
                       before enrollment;&#xD;
&#xD;
                   10. Severe liver, kidney, heart, lung, brain and other major organ failure;&#xD;
&#xD;
                   11. Patients with hypertension that is difficult to control (systolic blood&#xD;
                       pressure ≥140 mmHg and diastolic blood pressure ≥90 mmHg) despite treatment&#xD;
                       with several hypotensive agents;&#xD;
&#xD;
                   12. Previous or current had idiopathic pulmonary fibrosis, interstitial&#xD;
                       pneumonia, pneumoconiosis, radioactive pneumonia, histopathological&#xD;
                       pneumonia (e.g., bronchitis, obliterans), drug-induced pneumonia, or&#xD;
                       screening stage CT with active pneumonia;&#xD;
&#xD;
                   13. Patients with abnormal coagulation function (INR &gt; 1.5 or prothrombin time&#xD;
                       (PT) &gt; ULN+4 seconds), bleeding tendency or receiving thrombolytic or&#xD;
                       anticoagulant therapy are allowed to receive low-dose LMWH or oral aspirin&#xD;
                       to prevent anticoagulant therapy during the trial;&#xD;
&#xD;
                   14. Urine protein ≥ ++ or confirmed 24 hour urine protein quantitation;&#xD;
&#xD;
                   15. Patients with cardiac clinical symptoms or diseases that are not well&#xD;
                       controlled,such as:(1) NYHA2 or above heart failure;(2) Unstable angina;(3)&#xD;
                       Myocardial infarction occurred within 1 year;(4) Clinically significant&#xD;
                       supraventricular or ventricular arrhythmias require treatment or&#xD;
                       intervention;(5) QTc &gt; 470ms;&#xD;
&#xD;
                   16. Inability to swallow pills, malabsorption syndrome, or any condition that&#xD;
                       affects gastrointestinal absorption;&#xD;
&#xD;
                   17. In the 6 months prior to enrollment, patients had been arteriovenous&#xD;
                       thrombosis (AVT), such as cerebrovascular accident (including temporary&#xD;
                       ischemic attack, cerebral hemorrhage, cerebral infarction), deep vein&#xD;
                       thrombosis (DVT) and pulmonary embolism;&#xD;
&#xD;
                   18. Patients with a history of hereditary or acquired bleeding or coagulation&#xD;
                       disorders.There were clinically significant bleeding symptoms or definite&#xD;
                       bleeding tendency within 3 months before enrollment, such as&#xD;
                       gastrointestinal bleeding and hemorrhagic gastric ulcer;&#xD;
&#xD;
                   19. According to the judgment of the researcher, the patients have other factors&#xD;
                       that may lead to the forced termination of this study, such as other serious&#xD;
                       diseases (including mental diseases) requiring combined treatment, severe&#xD;
                       laboratory test abnormalities, accompanied by family or social factors,&#xD;
                       which will affect the safety of the subjects, or the collection of data.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Li Xiao, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Zhongshan Hospital Xiamen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Li Xiao, Doctor</last_name>
    <phone>2292201</phone>
    <phone_ext>0592</phone_ext>
    <email>xiaolibohan@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Zhongshan Hospital Affiliated to Xiamen University</name>
      <address>
        <city>Xiamen</city>
        <state>Fujian</state>
        <zip>361000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shuntian Cai</last_name>
      <phone>+86 18030190632</phone>
      <email>nktianxingjian@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>October 10, 2020</study_first_submitted>
  <study_first_submitted_qc>October 10, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 19, 2020</study_first_posted>
  <last_update_submitted>October 10, 2020</last_update_submitted>
  <last_update_submitted_qc>October 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 19, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Apatinib</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

